4D-150 Intravitreal Gene Therapy: Phase II & Phase III Data
Time: 12:00 pm
day: Conference Day One
Details:
- Understanding the advantages of intravitreal injection platform to appreciate superior delivery method over competing approaches
- Examining the unbelievably earth-shatteringly safe Phase III wet AMD trial data to recognize breakthrough safety profiles in gene therapy
- Exploring the scientific evidence behind customized capsids to understand why 4DMT has solved safety challenges where nobody else has
